Huddersfield scalp cooling device manufacturer Paxman has acquired Swedish counterpart Dignitana. The two companies will merge to create a new, unified group named Paxman AB.
The deal begins a new chapter in chemotherapy side effect management for Paxman and Dignitana.
As two companies once working in competition, the merger will enable valuable collaboration and connections, the sharing of new perspectives, and leverage of each other’s strengths, to improve patient outcomes.
Richard Paxman OBE, CEO of Paxman, said: “I am truly looking forward to collaborating, connecting, and combining the best of our two organisations, with new perspectives and shared strengths as we move forward.”
